Panel against expanded Fentora approval

Share this article:
Cephalon's Fentora
Cephalon's Fentora

An FDA advisory panel ruled against expanded use of Cephalon's powerful pain reliever Fentora as a treatment for non-cancer patients.

The panel ruled 17 to 3 against expanded approval.

Panel members were unconvinced by Cephalon's plan to ensure the drug doesn't fall into the wrong hands. That plan calls for restricting the number of physicians who can prescribe it and radio-frequency identification devices to be attached to shipments of the drug.

Nearly all of the 20 panel members also said they would like to see more information from Cephalon about the drug's efficacy.

Thomas Weisel analyst Donald Ellis said in a published report that the tone of the meeting was positive, and he thinks Cephalon will eventually persuade the FDA to widen Fentora's label. He deemed label expansion “a matter of when -- not if.”

Ellis added that he did not expect approval at Tuesday's panel meeting. While the panel could have recommended outright rejection for the request, he said it recommended further study instead.

Cephalon has already started a trial comparing Fentora to an instant-release form of the drug oxycodone.

Fentora and its predecessor Actiq are approved by the FDA only for use in cancer patients, but are known to be prescribed by doctors as an “off-label” treatment for conditions such as headaches and back pain.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...